Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 65

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Triple negative breast cancer

Not recruiting

Study of Nadunolimab with Gemcitabine and Carboplatin for Patients with Advanced Triple Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Cantargia AB

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Metformin to Prevent High Blood Sugar in Advanced Breast Cancer Patients with Alpelisib and Endocrine Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Medica Scientia Innovation Research S.L.

Malignant peritoneal neoplasm+3

Not recruiting

Study of Farletuzumab Ecteribulin vs. Chemotherapy for Women with Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Bristol Myers Squibb International Corporation

Cervix carcinoma

Not recruiting

Study on Tisotumab Vedotin, Bevacizumab, Carboplatin, and Pembrolizumab for Patients with Recurrent or Stage IVB Cervical Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Breast cancer metastatic

Not recruiting

Study of [177Lu]Lu-NeoB and Capecitabine for Patients with Advanced Breast Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Novartis Pharma AG

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Hormone-refractory prostate cancer

Not recruiting

Study of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Essa Pharma Inc.

Genitourinary syndrome of menopause

Not recruiting

Study on the Effectiveness of Platelet-Rich Plasma and Hyaluronic Acid vs. Estriol for Women with Menopausal Genitourinary Syndrome

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Estriol
  • Sponsor:Santiago Dexeus Font Fundacio Privada

Triple negative breast cancer

Not recruiting

Study on the Effectiveness of Carboplatin and Olaparib for Patients with Triple-Negative Breast Cancer with Positive HRD Status

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group

Ovarian cancer stage III

Not recruiting

Study on the Effect of Hyperthermic Intraperitoneal Chemotherapy with Cisplatin for Stage III Ovarian Cancer Patients Undergoing Surgery

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Breast cancer

Not recruiting

Study on the Safety and Effectiveness of Vepdegestrant and PF-07220060 for Adults with ER+/HER2- Advanced or Metastatic Breast Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:(3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
  • Sponsor:Pfizer Inc.

Breast cancer

Not recruiting

Study on Ribociclib, Alpelisib, and Letrozole for Adults with Advanced Hormone Receptor-Positive Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.